Navacaprant, a Novel Kappa Opioid Receptor Antagonist for Major Depressive Disorder: A Randomized Placebo-Controlled Phase 2 Trial

Authors
Category Primary study
JournalBiological Psychiatry
Year 2024
This article has no abstract
Epistemonikos ID: 267d0aa1be0f9d4a527b48a81867c27a5519413e
First added on: Feb 17, 2025